Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Strides Pharma ScienceNSE:STAR +1.21%67 Debt-to-Equity is 0.57 as of Mar. 2026, which is 46% below its 10-year median of 1.06. GuruFocus rates NSE:STAR with a GF Score™ of 67/100 and a GF Value™ of ₹763.71 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 814 Drug Manufacturers companies, Strides Pharma Science ranks worse than 73.1% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Strides Pharma Science's Debt-to-Equity or its related term are showing as below:
NSE:STAR'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.57 Med: 1.06 Max: 1.37
Current: 0.57
During the past 13 years, the highest Debt-to-Equity Ratio of Strides Pharma Science was 1.37. The lowest was 0.57. And the median was 1.06.
NSE:STAR's Debt-to-Equity is ranked worse than 73.1% of 814
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs NSE:STAR: 0.57
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Strides Pharma Science Debt-to-Equity Related Terms
Strides Pharma Science Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Strides Pharma Science's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strides Pharma Science Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Strides Pharma Science's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strides Pharma Science (NSE:STAR) has a Debt-to-Equity of 0.57 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Strides Pharma Science and its competitors. This is 46% below median its historical median of 1.06. Over the past decade, Strides Pharma Science's Debt-to-Equity has ranged from 0.57 to 1.37. According to the industry distribution chart, Strides Pharma Science ranks #595 out of 814 companies in the Drug Manufacturers industry, placing it in the top 73.1%.
Is Strides Pharma Science's Debt-to-Equity too high?
Strides Pharma Science's current Debt-to-Equity of 0.57 is 46% below median its 10-year median of 1.06. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 1.37. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Strides Pharma Science's value of 0.57 is 111.1% above this industry median. Based on the distribution chart, Strides Pharma Science ranks #595 out of 814 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Strides Pharma Science has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Strides Pharma Science ranks #595 out of 814 companies for Debt-to-Equity. This places Strides Pharma Science in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Strides Pharma Science's value of 0.57 is 111.1% above this benchmark. Historically, Strides Pharma Science's own Debt-to-Equity has ranged from 0.57 to 1.37 over the past decade. While the company's 10-year median is 1.06 vs. the industry median of 0.27, Strides Pharma Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strides Pharma Science's current Debt-to-Equity of 0.57 is 111.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Strides Pharma Science and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strides Pharma Science's current Debt-to-Equity is 0.57, which is 46% below median its own 10-year median of 1.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹763.71, compared to a current price of ₹1,072.80 — trading 40.5% above its estimated fair value. The current Debt-to-Equity is 0.57, which is 46% below median its 10-year median of 1.06 and 111.1% above the Drug Manufacturers industry median of 0.27. Strides Pharma Science's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current Debt-to-Equity is 0.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?
Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued.
The current stock price of ₹1,072.80 is trading 40.5% above its estimated GF Value™ of ₹763.71.
GuruFocus considers Strides Pharma Science to be Significantly Overvalued.
Key valuation signals for NSE:STAR:
Debt-to-Equity: 0.57 (46% below median its 10-year median of 1.06)
GF Value™: ₹763.71 vs. price of ₹1,072.80 (40.5% above fair value)
Industry Position: 111.1% above the Drug Manufacturers median (#595 of 814)
No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
67GF Score
Get the complete analysis for NSE:STAR
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:STAR has been successfully added to your 
